Yıl: 2020 Cilt: 3 Sayı: 2 Sayfa Aralığı: 117 - 125 Metin Dili: İngilizce DOI: 10.30714/j-ebr.2020259176 İndeks Tarihi: 18-10-2020

Millennium pandemic: A review of coronavirus disease (COVID-19)

Öz:
Coronaviruses, a large family of single-stranded RNA viruses, can infect humans and animals, and can cause neurological, gastrointestinal and hepatic diseases as well as causing various lung diseases, including pneumonia, with shortness of breath, cough and fever. At the end of December 2019, a group of health authorities reported unidentified cases of pneumonia in a seafood market in Wuhan, China. The World Health Organization (WHO) used term 2019 novel coronavirus (COVID-19) to refer to a coronavirus that affected the lower respiratory tract of patients with pneumonia in Wuhan, China on 29 December and the WHO announced that the official name of the 2019 novel coronavirus was coronavirus disease (COVID-19). COVID-19 is seen in many countries around the World and has been accepted as a pandemic by WHO. It is defined as a suspicious case with fever, sore throat, cough, and people with a history of traveling to China or some parts of the country, or someone who contact with a patient who has a history of travel in China or contact with a confirmed COVID-19 infection patient. Currently, there is no proven vaccine or antiviral therapy that can be used against animal or human coronavirus. To control the outbreak, the drugs must be developed as soon as possible. Various drugs have been used in the treatment of COVID-19 and the main ones are chloroquine, remdesivir, lopinavir/ritonavir, oseltamivir, favipiravir. Since the virus affects the whole World, vaccines and/or new curative antiviral drugs are needed to end the pandemic. For this purpose, large-scale observational studies are needed.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • [1]Weiss SR, Leibowitz JL. Coronavirus pathogenesis. Adv Virus Res. 2011;81:85– 164.
  • [2]WMHC. Wuhan Municipal Health and Health Commission’s Briefing on the Current Pneumonia Epidemic Situation in Our City. 2020. [cited 2020 21 March]; Available from: ttp://wjw.wuhan.gov.cn/front/web/showDet ail/2019123108989.
  • [3]In: Richman DD, Whitley RJ, and Hayden FG (Eds) Clinical virology. 4th Edition. ASM Press Washington DC; 1-1489, 2017.
  • [4]Chan-Yeung M, Xu RH. SARS: epidemiology. Respirology. 2003;8 Suppl:S9–S14.
  • [5]Middle East Respiratory Syndrome Coronavirus. Available.; Available from: https://www.who.int/emergencies/merscov/en/. [cited 2020 21 March]
  • [6]Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020;382(10):929–936.
  • [7]Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [published correction appears in Lancet. 2020 Jan 30;:]. Lancet. 2020;395(10223):497–506.
  • [8]Cohen J. Wuhan seafood market may not be source of novel virus spreading. Available from: https://www.sciencemag.org/news/2020/01/ wuhan-seafood-market-may-not-be-sourcenovel-virus-spreading-globally.
  • [9]WHO. Novel Coronavirus–China. 2020. [cited 2020 22 March]; Available from: https://www.who.int/csr/don/12-january2020-novel-coronavirus-china/en/.
  • [10]Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). 2020.; Available from: https://www.who.int/news-room/detail/30- 01-2020-statement-on-the-second-meetingof-the-international-healthregulations- (2005)-emergency-committee-regardingthe-outbreak-of novelcoronavirus-(2019- ncov. [cited 2020 22 March].
  • [11]National Health Commission of the People’s Republic of China. Diagnosis and treatment of new coronavirus pneumonia (version 5).; Available from: http://www. nhc.gov.cn. [cited 2020 23 March]
  • [12]Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating personto-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514–523.
  • [13]Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513.
  • [14]Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention [published online ahead of print, 2020 Feb 24]. JAMA. 2020;10.1001/jama.2020.2648.
  • [15]Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020;382(13):1199–1207.
  • [16]Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China [published online ahead of print, 2020 Feb 7]. JAMA. 2020;e201585.
  • [17]Ai T, Yang Z, Hou H, et al. Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases [published online ahead of print, 2020 Feb 26]. Radiology. 2020;200642.
  • [18]Pan F, Ye T, Sun P, et al. Time Course of Lung Changes On Chest CT During Recovery From 2019 Novel Coronavirus (COVID-19) Pneumonia [published online ahead of print, 2020 Feb 13]. Radiology. 2020;200370.
  • [19]Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study [published online ahead of print, 2020 Feb 24]. Lancet Infect Dis. 2020;S1473- 3099(20)30086-4.
  • [20]Pan Y, Guan H, Zhou S, et al. Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China [published online ahead of print, 2020 Feb 13]. Eur Radiol. 2020;10.1007/s00330-020-06731-x.
  • [21]Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome [published online ahead of print, 2020 Feb 18] [published correction appears in Lancet Respir Med. 2020 Feb 25;:]. Lancet Respir Med. 2020;S2213-2600(20)30076-X.
  • [22]Nassar MS, Bakhrebah MA, Meo SA, et al. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: epidemiology, pathogenesis and clinical characteristics. Eur Rev Med Pharmacol Sci. 2018;22(15):4956–4961.
  • [23]van den Brand JM, Smits SL, Haagmans BL. Pathogenesis of Middle East respiratory syndrome coronavirus. J Pathol. 2015;235(2):175–184.
  • [24]Hui DSC, Zumla A. Severe Acute Respiratory Syndrome: Historical, Epidemiologic, and Clinical Features. Infect Dis Clin North Am. 2019;33(4):869–889.
  • [25]Huang P, Liu T, Huang L, et al. Use of Chest CT in Combination with Negative RT-PCR Assay for the 2019 Novel Coronavirus but High Clinical Suspicion. Radiology. 2020;295(1):22–23..
  • [26]Yu F, Du L, Ojcius DM, et al. Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. Microbes Infect. 2020;22(2):74–79.
  • [27]Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019- nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3):2000045.
  • [28]The Lancet Infectious Diseases. Challenges of coronavirus disease 2019. Lancet Infect Dis. 2020;20(3):261.
  • [29]Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019- nCoV) infected pneumonia (standard version). Mil Med Res. 2020;7(1):4.
  • [30]Aguiar ACC, Murce E, Cortopassi WA, et al. Chloroquine analogs as antimalarial candidates with potent in vitro and in vivo activity. Int J Parasitol Drugs Drug Resist. 2018;8(3):459–464.
  • [31]Savarino A, Boelaert JR, Cassone A, et al. Effects of chloroquine on viral infections: an old drug against today's diseases?. Lancet Infect Dis. 2003;3(11):722–727.
  • [32]Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69. Published 2005 Aug 22.
  • [33]Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019- nCoV) in vitro. Cell Res. 2020;30(3):269– 271.
  • [34]Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72–73.
  • [35]Agostini ML, Andres EL, Sims AC, et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio. 2018;9(2):e00221- 18.
  • [36]Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020;382(10):929–936.
  • [37]Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERSCoV. Nat Commun. 2020;11(1):222.
  • [38]Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252–256.
  • [39]National Health Commission of the People's Republic of China. Notice on printing and distributing the diagnosis and treatment plan of pneumonia with new coronavirus infection (trial version 3). . [cited 2020 24 March]; Available from: http://www.nhc.gov.cn/yzygj/ s7653p/202001/f492c9153ea9437bb587ce2ffcb ee1fa. shtml.
  • [40]Chow EJ, Doyle JD, Uyeki TM. Influenza virusrelated critical illness: prevention, diagnosis, treatment. Crit Care. 2019;23(1):214.
  • [41]Shi H, Han X, Zheng C. Evolution of CT Manifestations in a Patient Recovered from 2019 Novel Coronavirus (2019-nCoV) Pneumonia in Wuhan, China. Radiology. 2020;295(1):20.
  • [42]Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res. 2018;153:85–94.
  • [43]News. Available from: http://www.szdsyy.com/News/0a6c1e58-e3d0- 4cd1-867a-d5524bc59cd6.html [cited 2020 22 March];
  • [44]Chen C, Huang J, Cheng Z et al., Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv, 2020. doi: https://doi.org/10.1101/2020.03.17.200374 32
  • [45]Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China [published online ahead of print, 2020 Feb 19]. Allergy. 2020;10.1111/all.14238.
  • [46]Yuan M, Yin W, Tao Z, et al Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China. PLoS One. 2020;15(3):e0230548.
  • [47]Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–337.
  • [48]Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University; Available from: https://coronavirus.jhu.edu/map.html
APA Bilgin S, KURTKULAĞI O, KAHVECİ G, Duman T, TEL B (2020). Millennium pandemic: A review of coronavirus disease (COVID-19). , 117 - 125. 10.30714/j-ebr.2020259176
Chicago Bilgin Satılmış,KURTKULAĞI Ozge,KAHVECİ Gizem BAKİR,Duman Tuba,TEL Burcin Meryem ATAK Millennium pandemic: A review of coronavirus disease (COVID-19). (2020): 117 - 125. 10.30714/j-ebr.2020259176
MLA Bilgin Satılmış,KURTKULAĞI Ozge,KAHVECİ Gizem BAKİR,Duman Tuba,TEL Burcin Meryem ATAK Millennium pandemic: A review of coronavirus disease (COVID-19). , 2020, ss.117 - 125. 10.30714/j-ebr.2020259176
AMA Bilgin S,KURTKULAĞI O,KAHVECİ G,Duman T,TEL B Millennium pandemic: A review of coronavirus disease (COVID-19). . 2020; 117 - 125. 10.30714/j-ebr.2020259176
Vancouver Bilgin S,KURTKULAĞI O,KAHVECİ G,Duman T,TEL B Millennium pandemic: A review of coronavirus disease (COVID-19). . 2020; 117 - 125. 10.30714/j-ebr.2020259176
IEEE Bilgin S,KURTKULAĞI O,KAHVECİ G,Duman T,TEL B "Millennium pandemic: A review of coronavirus disease (COVID-19)." , ss.117 - 125, 2020. 10.30714/j-ebr.2020259176
ISNAD Bilgin, Satılmış vd. "Millennium pandemic: A review of coronavirus disease (COVID-19)". (2020), 117-125. https://doi.org/10.30714/j-ebr.2020259176
APA Bilgin S, KURTKULAĞI O, KAHVECİ G, Duman T, TEL B (2020). Millennium pandemic: A review of coronavirus disease (COVID-19). Experimental Biomedical Research, 3(2), 117 - 125. 10.30714/j-ebr.2020259176
Chicago Bilgin Satılmış,KURTKULAĞI Ozge,KAHVECİ Gizem BAKİR,Duman Tuba,TEL Burcin Meryem ATAK Millennium pandemic: A review of coronavirus disease (COVID-19). Experimental Biomedical Research 3, no.2 (2020): 117 - 125. 10.30714/j-ebr.2020259176
MLA Bilgin Satılmış,KURTKULAĞI Ozge,KAHVECİ Gizem BAKİR,Duman Tuba,TEL Burcin Meryem ATAK Millennium pandemic: A review of coronavirus disease (COVID-19). Experimental Biomedical Research, vol.3, no.2, 2020, ss.117 - 125. 10.30714/j-ebr.2020259176
AMA Bilgin S,KURTKULAĞI O,KAHVECİ G,Duman T,TEL B Millennium pandemic: A review of coronavirus disease (COVID-19). Experimental Biomedical Research. 2020; 3(2): 117 - 125. 10.30714/j-ebr.2020259176
Vancouver Bilgin S,KURTKULAĞI O,KAHVECİ G,Duman T,TEL B Millennium pandemic: A review of coronavirus disease (COVID-19). Experimental Biomedical Research. 2020; 3(2): 117 - 125. 10.30714/j-ebr.2020259176
IEEE Bilgin S,KURTKULAĞI O,KAHVECİ G,Duman T,TEL B "Millennium pandemic: A review of coronavirus disease (COVID-19)." Experimental Biomedical Research, 3, ss.117 - 125, 2020. 10.30714/j-ebr.2020259176
ISNAD Bilgin, Satılmış vd. "Millennium pandemic: A review of coronavirus disease (COVID-19)". Experimental Biomedical Research 3/2 (2020), 117-125. https://doi.org/10.30714/j-ebr.2020259176